Guideline of Chronic Urticaria Beyond - Wikidata - wikimedia - TriplyDB

Guideline of Chronic Urticaria Beyond

Guideline of Chronic Urticaria Beyond

http://www.wikidata.org/entity/Q26743369

about

Increased Risk of Chronic Spontaneous Urticaria in Patients With Autoimmune Thyroid Diseases: A Nationwide, Population-based Study.Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence.Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014.Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.Therapy of antihistamine-resistant chronic spontaneous urticaria.A Case of Type 2 Hereditary Angioedema With SERPING1 Mutation.Clinical Course of Chronic Spontaneous Urticaria in the Korean Adult Population.Etiology of chronic urticaria: the Ecuadorian experience.Urticaria and Angioedema: an Update on Classification and Pathogenesis.

P2860

Q33734366-FBFA5009-63DD-4195-B934-FF3677595604 Q38682862-DFD5C27C-D963-4DC5-BF01-EC26F317DBD7 Q38693457-22A26DA0-0D32-48CD-9EC7-CB4D391F4B8A Q38740314-0FCC889F-528B-434D-BBD4-9FC8D70E623A Q38981770-E65BC09F-C01C-4243-89F6-3D39EF8E443A Q42371150-46BC16E7-DD49-416C-9A65-FA6DCA2EA6F1 Q47105217-4A673D3D-8500-4542-B5AB-D70B10FD700E Q47118210-20183E37-759A-445C-894B-24E1217CCF6A Q48339085-BA150166-68E6-40DC-9CC7-B787CAF38256

P2860

Guideline of Chronic Urticaria Beyond

http://www.wikidata.org/entity/Q26743369

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Guideline of Chronic Urticaria Beyond

@ast

Guideline of Chronic Urticaria Beyond

@en

Guideline of Chronic Urticaria Beyond

@nl

type

label

Guideline of Chronic Urticaria Beyond

@ast

Guideline of Chronic Urticaria Beyond

@en

Guideline of Chronic Urticaria Beyond

@nl

prefLabel

Guideline of Chronic Urticaria Beyond

@ast

Guideline of Chronic Urticaria Beyond

@en

Guideline of Chronic Urticaria Beyond

@nl

P1433

Q26743369-3B7D01F5-CA98-496F-8D21-A19E86FC0B6B

P1476

Q26743369-B9CECBCB-F9CF-463F-80BD-B59383EA2CF9

P2093

Q26743369-1BF926E3-C69B-4350-BC92-E46F1569E9CF

Q26743369-89422005-0B40-47EC-BF75-729F03E3CF57

P2860

Q26743369-03F4C61C-5718-4433-9EB3-603819C2AA39

Q26743369-0536EBCC-5D2D-426C-BD03-3DB0B19D30EC

Q26743369-056FF9D6-E36D-4FD1-BA1E-D8F8890639B1

Q26743369-05930644-98E1-47F6-B19C-9E597C383562

Q26743369-0C3E3622-169D-4DF8-89DE-4E0E3DCF2462

Q26743369-0FDE86B8-9F71-44A5-8FCC-4D5EC4E4FA3E

Q26743369-11D41A44-33FF-4731-BBD3-567770BAF4AD

Q26743369-1407A868-2039-40E8-BC9B-F665AFD12106

Q26743369-18399EF7-0352-4153-BE95-C74D8D5DAC19

Q26743369-1AC018B7-353A-4C0B-B929-6CF3B71AD308

P304

Q26743369-E5C8F577-67E1-4D16-8A3B-BA05044587BC

P31

Q26743369-FA3B5861-1284-4B66-BE3A-2B9325057CCB

P3181

Q26743369-A7D45333-7E2E-4E3C-9668-E35B244C41E4

P356

Q26743369-2CC136C4-2252-4141-957B-40007E3EBE95

P407

Q26743369-837CEB39-4651-4B81-ACB8-7BB7428F5CDE

P433

Q26743369-53166A1C-3238-4640-A95D-F0713F036939

P478

Q26743369-DCF9C887-63BD-4202-BE05-570722F57FA5

P577

Q26743369-89761DD0-859B-45E3-8701-7A51AB2A6BFC

P698

Q26743369-8AFCAAEC-97F1-4A30-9322-70EB8F87DDA8

P932

Q26743369-D7922B1B-0018-41F7-90DA-0C984754FBD1

P3181

P356

AAIR.2016.8.5.396

P1433

Allergy, Asthma & Immunology Research

P1476

Guideline of Chronic Urticaria Beyond

@en

P2093

Jonathan A Bernstein

http://www.w3.org/2001/XMLSchema#string

Lauren M Fine

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an antibody directed against IgE

Safety and tolerability of omalizumab.

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.

The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine.

Chronic urticaria: pathogenesis and treatment.

Omalizumab in asthma: approval and postapproval experience.

P304

396-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3774097

http://www.w3.org/2001/XMLSchema#string

P356

10.4168/AAIR.2016.8.5.396

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27334777

http://www.w3.org/2001/XMLSchema#string

P932

4921693

http://www.w3.org/2001/XMLSchema#string